About CATALIS
CATALIS is a Healthcare company based in Montreal (Canada) founded in 2017. Consulting services for clinical drug development and trials are provided. CATALIS has raised $1.18 million across 1 funding round from investors including Merck, AbbVie and Pfizer. CATALIS offers products and services including FAST TRACK Evaluation Service, Personalized Support Service, and Clinical Trials Quebec. Its focus areas include Biopharma Outsourcing, Consulting and Clinical Development.
Company details
CATALIS was founded in 2017 in Montreal, Canada, as a provider of consulting services in the biopharmaceutical sector. Operations center on clinical drug development, with support for phase I, II, and III trials. Expertise is applied to pharmacology, biomarkers, and biopharmaceutical devices, assisting clients in regulatory and operational aspects of drug advancement. Services are delivered to facilitate efficient trial execution and development processes.
- Headquarters Montreal, Canada
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website catalisquebec.com
- Social LinkedIn X
- Total Equity Funding$1.18M (USD)
in 1 rounds
- Latest Funding Round$1.18M (USD), Seed
Jun 2019
- InvestorsMerck
& 7 more
Products & Services of CATALIS
CATALIS offers a comprehensive portfolio of products and services, including FAST TRACK Evaluation Service, Personalized Support Service, and Clinical Trials Quebec.
Accelerates authorization for clinical trials in Quebec
Offers tailored assistance for clinical research stakeholders
Facilitates tools and resources for conducting clinical trials
Funding Insights of CATALIS
CATALIS has successfully raised a total of $1.18M through 1 strategic funding round. The most recent funding activity was a Seed round of $1.18 million completed in June 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.18M
- Total Rounds 1
- Last Round Seed — $1.18M
- First Round $1.18M
(Jun 2019)
- Investors Count 8
All 1 funding rounds of CATALIS with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
8 investors in total: 8 institutional.
Investors in CATALIS
CATALIS has secured backing from 8 investors, including institutional investors. Prominent investors backing the company include Merck, AbbVie and Pfizer.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Developer of pharmaceuticals and vaccines for various therapeutic areas | 1715 | gsk.com | Brentford, United Kingdom | |
Pharmaceutical products for treating multiple diseases are provided. | 1849 | pfizer.com | New York, United States | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | abbvie.com | Chicago, United States | |
Takeda Pharmaceuticals is engaged in developing innovative medicines globally. | 1781 | takeda.com | Tokyo, Japan | |
Pharmaceutical therapies for cancers and neurological disorders are developed. | 1954 | servier.com | Suresnes, France | |
R&D focused on manufacturing of drugs for multiple therapeutic areas | 1996 | novartis.com | Basel, Switzerland | |
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | merck.com | Kenilworth, United Kingdom | |
Pharmaceuticals and diagnostics kits are developed for various diseases. | 1896 | roche.com | Basel, Switzerland |
Investor details for CATALIS
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of CATALIS
2 dated milestones of CATALIS across 2 years, from founding to its latest funding, stage changes and deals.
- Founded CATALIS is founded.
- Funding First funding round of $1.2M.
Web traffic of CATALIS
The website of CATALIS (catalisquebec.com) receives about 4.1K visits a month.
- Monthly visits4.1K
▲ 5.5% vs previous month
Websites whose visitors overlap most with CATALIS. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
cqc-qcc.ca | cqc-qcc.ca | 100% | #6,153,769 | – | |
gastrosaintejustine.org | gastrosaintejustine.org | 90% | #9,443,115 | – | |
geoq.info | geoq.info | 86% | #1,804,611 | – | |
| mcsa.ca | 84% | 5K | #3,884,188 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Catalis
Complete news archive for CATALIS
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CATALIS
CATALIS was founded in 2017 and raised its 1st funding round 2 years after it was founded.
CATALIS is headquartered in Montreal, Canada. It is registered at Montreal, Quebec, Canada.
CATALIS is a funded company, having raised a total of $1.18M across 1 funding round to date. The company's 1st funding round was a Seed of $1.18M, raised on Jun 2019.
CATALIS was founded in 2017 in Montreal, Canada, as a provider of consulting services in the biopharmaceutical sector. Operations center on clinical drug development, with support for phase I, II, and III trials. Expertise is applied to pharmacology, biomarkers, and biopharmaceutical devices, assisting clients in regulatory and operational aspects of drug advancement. Services are delivered to facilitate efficient trial execution and development processes.
CATALIS offers FAST TRACK Evaluation Service, Personalized Support Service, and Clinical Trials Quebec.